Targeted metabolism creates possibilities for lung cancer treatment in the precision tumor era

Lung cancer has emerged as the primary cause of cancer-related deaths worldwide, and advances in its treatment are critically needed. Despite significant breakthroughs in molecular targeted therapy and immunotherapy in lung cancer, the overall prognosis for patients remains poor. In the era of precision medicine, the pivotal role of tumor metabolic reprogramming in the onset and progression of lung cancer has become increasingly evident. Preclinical studies have demonstrated the potential efficacy of targeting tumor metabolic pathways, thereby suggesting new avenues for lung cancer treatment research. A comprehensive understanding of the regulatory mechanisms underlying these metabolic pathways could hold potential for developing innovative therapies and improving patient outcomes in the future. This review summarizes the latest research in glucose metabolism, lipid metabolism, protein metabolism, and nucleotide metabolism in lung cancer. It further examines the role these metabolic pathways play in lung cancer pathogenesis and explores their potential as therapeutic targets.